GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. Its stock price is heavily dependent on the success of its targeted drug. The chart reflects sales growth and clinical trial results to expand its use.
Share prices of companies in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. We've categorized it as "Targeted Oncology." The chart below shows how the market views personalized medicine approaches in oncology.
Broad Market Index - GURU.Markets
Aadi Bioscience is an oncology company developing targeted therapies for patients with genetic mutations. As a component of the GURU.Markets index, it represents the personalized medicine sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AADI - Daily change in the company's share price Aadi Bioscience
Aadi Bioscience, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures its sensitivity to news about its oncology drug sales and new research results.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets tumors with specific genetic mutations. Oncology is a volatile sector. The chart below reflects the average fluctuations in this industry, providing context for evaluating AADI stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Aadi Bioscience is a biotech company focused on treating rare cancers. Its shares are subject to anticipation of clinical trial results and regulatory decisions. These sharp, event-driven movements are part of a complex volatility mosaic.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aadi Bioscience
Aadi Bioscience's year-over-year performance is a story about the commercialization of its drug for the treatment of a rare cancer. Its market capitalization growth over the past 12 months reflects the sales volume of this niche product, but also, more importantly, the results of studies on its use in other tumor types with the TSC mutation, which could significantly expand its market.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Aadi Bioscience is a commercial-stage biopharmaceutical company focused on treating rare cancers. Its success depends on the commercialization of its key drug. The chart shows how its niche strategy and efforts to expand the reach of its drug are impacting its performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aadi Bioscience, an oncology company developing targeted therapies, is a classic example of the biotech sector. Its annual market capitalization dynamics are driven by news about clinical trials and regulatory approvals. The success of a single drug can lead to explosive growth, ignoring macroeconomic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aadi Bioscience
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Its monthly growth is driven by sales of its drug Fyarro and progress in expanding its indications. Quarterly revenue reports are the main drivers.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with rare genetic mutations. The chart below reflects the general sentiment in the oncology sector, where personalized medicine is a key trend.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Its dynamics are a combination of stability from sales of its existing drug and volatility from news on new studies. This makes its movement independent of general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aadi Bioscience
Shares of Aadi Bioscience, an oncology company, are news-sensitive. Weekly price movements depend on sales data for their targeted drug and the results of new clinical trials. The chart below shows how short-term commercial and scientific events affect the valuation of a company with a single key product.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Aadi Bioscience is an oncology company whose drug targets tumors with a specific genetic mutation. It's an example of personalized medicine. The chart illustrates how its narrow focus and scientific data create a unique investment profile, distinct from the broader pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aadi Bioscience is a biotech company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Its stock price movements are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
AADI - Market capitalization of the company Aadi Bioscience
Aadi Bioscience's market capitalization is the valuation of its targeted drug for the treatment of rare cancers associated with mutations in the mTOR gene. The company's value depends on the successful commercialization of this niche but important drug. The chart shows how investors value its scientific platform.
AADI - Share of the company's market capitalization Aadi Bioscience within the market segment - Oncology targeted therapy
Aadi Bioscience's market share in targeted oncology is focused on treating rare cancers with specific genetic mutations. Its market share is determined by the success of its drug, making it a shining example of how a company can become a leader in a narrow but vital niche.
Market capitalization of the market segment - Oncology targeted therapy
The chart below is a barometer of the biotech sector focused on targeted cancer therapy. Aadi Bioscience is a niche player with a drug for rare tumors. The dynamics in the chart reflect how the market views this area of personalized oncology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with rare cancers. Aadi Bioscience's market cap reflects the valuation of its targeted drug, which targets tumors with a specific genetic mutation. The line shows how precision oncology is making a small, yet vital, contribution to global medicine.
Book value capitalization of the company, segment and market as a whole
AADI - Book value capitalization of the company Aadi Bioscience
Aadi Bioscience's book value represents its scientific and commercial capital. The chart below reflects the valuation of its rights to FYARRO®, a drug designed to treat a rare cancer. The dynamics show how the company is monetizing its core asset and investing in expanding its use.
AADI - Share of the company's book capitalization Aadi Bioscience within the market segment - Oncology targeted therapy
Aadi Bioscience's core assets are its R&D centers and infrastructure for commercializing drugs for treating rare cancers. The chart shows the company's share of this specialized scientific and commercial infrastructure.
Market segment balance sheet capitalization - Oncology targeted therapy
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Aadi Bioscience, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Aadi Bioscience specializes in treating cancer tumors with specific genetic mutations. The company's assets aren't huge factories, but rather a high-precision drug and a scientific platform for targeted therapy. The chart below demonstrates the financial weight behind this "sniper" approach to oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aadi Bioscience
Aadi Bioscience is an oncology company with an approved drug. Its market capitalization reflects the current sales of this drug and its potential to treat other cancers, making it less speculative than early-stage biotechs.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Aadi Bioscience, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. Its value is entirely dependent on the success of its drugs in clinical trials. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current tangible assets.
Market to book capitalization ratio for the market as a whole
Aadi Bioscience is a biopharmaceutical company specializing in targeted cancer therapy. This chart shows how the market views their approved drug and its potential for expanded use. The dynamics reflect commercial success and the results of new clinical trials.
Debts of the company, segment and market as a whole
AADI - Company debts Aadi Bioscience
Aadi Bioscience, a commercial biotech company, is leveraging its financial structure to market its approved drug for a rare cancer. This chart shows how the company is investing in building a sales force and conducting post-approval studies to expand the use of its key asset.
Market segment debts - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. This chart shows how its leverage reflects the transition from clinical development to commercialization of its first drug, which requires significant investments in marketing and sales to enter the competitive oncology market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aadi Bioscience
African Agriculture aims to develop agriculture in Africa, potentially to an industrial scale. This requires massive investments in land, irrigation, and machinery. This chart shows how the company utilizes capital to implement its large-scale, capital-intensive projects in the emerging market.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Aadi Bioscience is a commercial biopharmaceutical company focused on developing drugs to treat cancers with specific genetic mutations. This chart compares its debt to the total market capitalization of the entire oncology sector. It shows how the company is funding the commercialization of its first approved drug and further research.
Debt to book value of all companies in the market
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets tumors with specific genetic mutations. Bringing the drug to market requires significant marketing expenditures. This total debt chart helps assess how Aadi is funding the commercialization of its niche oncology drug in a competitive environment.
P/E of the company, segment and market as a whole
P/E - Aadi Bioscience
This chart shows the valuation of Aadi Bioscience, an oncology company with an approved drug. Its P/E will depend on the successful commercialization of this drug and its potential to treat other types of cancer. This is an assessment of the company's ability to move from development to successful sales.
P/E of the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers with specific genetic mutations. Its flagship drug targets tumors with mutations in the TSC genes. This chart shows the average valuation for the oncology sector, reflecting how investors value precision medicine that targets specific genetic drivers of cancer.
P/E of the market as a whole
Aadi Bioscience is a biopharmaceutical company focused on developing treatments for genetically determined cancers. Its lead drug targets tumors with mutations in the TSC1 or TSC2 genes. This risk appetite chart helps understand how investors value companies in the precision oncology field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. This graph reflects market expectations regarding the commercial success of its drug. Future revenue depends on expanding its indications.
%20P%2FE%20Aadi%20Bioscience&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aadi-Bioscience&v=1772513490955 "Chart of the company's future (projected) P/E Aadi Bioscience")
Future (projected) P/E of the market segment - Oncology targeted therapy
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets rare cancers with specific genetic mutations. This chart shows how the market views the drug's commercial potential and prospects for expanding its use. It compares Aadi to other oncology companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772513490984 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for rare cancers. Its success depends on the results of clinical trials and the drug's commercialization. This chart, reflecting overall market optimism, influences investor willingness to fund companies operating in narrow but important niches in oncology.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513490996 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aadi Bioscience
Aadi Bioscience is a commercial-stage biopharmaceutical company focused on treating rare cancers. Its financial performance depends on sales of its approved drug, Fyarro. This chart shows how successful commercialization and indication expansion of the targeted drug impact the company's path to profitability.
Profit of companies in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. This graph, showing overall sector profitability, reflects the shift toward personalized medicine. The success of Aadi's drug in specific patient groups could have a profound impact on the entire oncology industry.
Overall market profit
Aadi Bioscience is a commercial biopharmaceutical company whose drug targets cancers with specific genetic mutations. Unlike development-stage companies, Aadi is already generating revenue, but its long-term growth still depends on the widespread adoption of its technology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. Future profit projections depend on sales of its drug, Fyarro. Analysts predict an increase in the number of patients and the expansion of the drug's use into new indications.
%20profit%20of%20the%20company%20Aadi%20Bioscience&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aadi-Bioscience&v=1772513491264 "Graph of future (projected) profit of the company Aadi Bioscience")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. This chart shows future revenue expectations for the entire targeted therapy segment, allowing one to assess how the company's approach to personalized oncology fits into the overall outlook for this cutting-edge field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772513491306 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. Demand for its drugs is driven by medical need. However, this timeline is important because the overall economic situation affects the solvency of healthcare systems and insurance companies, which can impact pricing and the speed of new drug adoption.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513491325 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aadi Bioscience
Aadi Bioscience is a commercial biopharmaceutical company focused on developing therapies for cancers with specific genetic mutations. This metric, which correlates market capitalization with sales of its first drug, is key. It reflects how investors view its commercial launch and potential for expanded indications.
P/S market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company developing treatments for cancers caused by genetic alterations in the mTOR pathway. Its drug targets specific mutations. This chart shows how investors value revenue in the targeted oncology sector, demonstrating their level of confidence in Aadi's scientific approach and commercial potential.
P/S of the market as a whole
Aadi Bioscience is a commercial biopharmaceutical company focused on developing and commercializing drugs for the treatment of genetically determined cancers. This chart helps understand how the market values companies that have already launched innovative oncology drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. This chart shows how the market values the company based on projected future sales of its approved drug. It reflects expectations for commercial success and expanded indications for this targeted therapy.
%20P%2FS%20Aadi%20Bioscience&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aadi-Bioscience&v=1772513491412 "The graph of the company's future (projected) P/S Aadi Bioscience")
Future (projected) P/S of the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing therapies for genetically determined cancers. The chart shows the average estimated future sales in the targeted oncology sector. It helps understand how investors view the commercial potential of its drug, FYARRO, and the prospects for expanding its use to other rare tumors.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772513491448 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Aadi Bioscience (AADI) is a biopharmaceutical company focused on treating rare cancers with specific genetic mutations. Their success depends on sales of their currently approved drug and the results of new studies. This graph doesn't reflect their potential in the field of personalized oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513491455 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aadi Bioscience
Aadi Bioscience is a commercial biotechnology company focused on cancer treatment. Its revenue is generated from sales of FYARRO, a drug designed to treat a rare type of sarcoma. This growth reflects the drug's successful introduction into clinical practice and its expanding use among oncologists.
Sales of companies in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. Its revenue is generated by sales of FYARRO. The sales structure demonstrates how successfully this targeted drug is carving out its niche in precision oncology.
Overall market sales
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers with specific genetic mutations. Its success depends on the commercialization of its drug and the results of new research. Demand for such targeted drugs is not dependent on economic cycles, but the overall situation shown in this chart affects the solvency of the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company specializing in the treatment of cancers with specific genetic mutations. Its sales are dependent on the commercial success of its first drug. This chart shows analysts' expectations for prescription growth and expanded indications.
%20sales%20of%20the%20company%20Aadi%20Bioscience&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aadi-Bioscience&v=1772513491719 "Schedule of future (projected) sales of the company Aadi Bioscience")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. This chart shows the forecast for the targeted oncotherapy sector. It reflects the shift toward personalized medicine, which is driving demand for precision therapies like those being developed by Aadi.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772513491748 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Aadi Bioscience. The company develops targeted therapies for cancer treatment. Its ability to fund research and commercialize drugs depends on the influx of capital into the industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513491822 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aadi Bioscience
Aadi Bioscience is a commercial biopharmaceutical company focused on treating cancers with specific genetic mutations. This chart shows its financial performance after the launch of its first drug. Profitability depends on sales volume, pricing strategy, and indication expansion.
Market segment marginality - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genetic mutations. Profitability depends on the success of its precision oncology drugs. This chart shows the average profitability in the pharmaceutical industry. It helps assess the success of its niche oncology strategy.
Market marginality as a whole
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. Its success depends on the commercialization of its approved drug and further research. This schedule, reflecting the overall economic situation, influences healthcare budgets, which determine the widespread use of new, expensive targeted drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Aadi Bioscience
Aadi Bioscience is a commercial biopharmaceutical company focused on treating rare cancers. This chart reflects the size of the team dedicated to research, marketing, and sales of the approved drug. Growth in the chart reflects efforts to expand the drug's applicability and increase sales.
Share of the company's employees Aadi Bioscience within the market segment - Oncology targeted therapy
Aadi Bioscience specializes in developing targeted therapies for cancers with specific genetic mutations. This chart shows the company's share of the total number of scientists working in precision oncology. This reflects its scientific focus and potential for treating rare and difficult-to-treat tumors.
Number of employees in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for cancers with genetic mutations. This chart, showing employment in the targeted oncology sector, is important. The growing number of scientists in this field reflects advances in personalized medicine and the desire to develop treatments for specific patient subgroups.
Number of employees in the market as a whole
Aadi Bioscience develops targeted therapies for rare cancers. Funding for such highly specialized research is only possible in developed economies. This overall employment chart reflects the state of the healthcare system, which can afford innovative and expensive drugs for orphan diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aadi Bioscience (AADI)
Aadi Bioscience (AADI) is a biopharmaceutical company focused on treating cancers with specific genetic mutations (based on mTOR technology). This chart is classic for biotech. The market value reflects solely the potential of their drug (Fyarro) and R&D, i.e., their "intellectual capital," not their staff.
%20of%20the%20company%20Aadi%20Bioscience%20(AADI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aadi-Bioscience-AADI&v=1772513492012 "Chart of market capitalization per employee (in thousands of dollars) of the company Aadi Bioscience (AADI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted cancer therapies. Its value is determined by the potential of a single key drug and the science behind it. This metric clearly demonstrates that in biotech, market valuation is often based on the intellectual property developed by a very small and specialized team.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772513492023 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Aadi Bioscience is a biopharmaceutical company focused on treating cancers with specific genetic mutations. Market capitalization in targeted oncology depends on the efficacy and niche nature of the drug. This chart illustrates how a small research team can create a product with enormous market value, targeting a specific patient group.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513492064 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aadi Bioscience (AADI)
Aadi Bioscience is a biotech company focused on treating cancers caused by specific genetic mutations (mTOR inhibitors). They have an approved drug, Fyarro. This chart shows how successfully their commercial team is selling this niche drug, and whether these revenues cover the R&D costs for its expansion.
%20Chart%20Aadi%20Bioscience%20(AADI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aadi-Bioscience-AADI&v=1772513492071 "Company Profit Per Employee (in thousands of dollars) Chart Aadi Bioscience (AADI)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Aadi Bioscience is a biopharmaceutical company focused on developing targeted therapies for the treatment of oncology. This chart reflects resource management efficiency during clinical trials. As their drug FYARRO commercializes, this metric should increase, demonstrating the transition from the costly R&D phase to generating stable revenue.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772513492078 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Aadi Bioscience (AADI) is a biopharmaceutical company whose key product, Fyarro, treats a rare cancer (PEComa). It's a biotech with a commercial product. This chart shows how a company with an approved but very niche drug generates profits. Employee efficiency depends on the high price of the drug and the efforts of a small team to sell it.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513492090 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aadi Bioscience (AADI)
Aadi Bioscience is a biopharmaceutical company focused on treating rare cancers. This chart shows the commercial success of their approved drug, Fyarro. High revenue per employee is a sign of the effectiveness of their commercial team and the drug's marketability in its niche.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aadi-Bioscience-AADI&v=1772513492103 "Sales chart per company employee Aadi Bioscience (AADI)")
Sales per employee in the market segment - Oncology targeted therapy
Aadi Bioscience is a biotech company that already has a commercial product (Fyarro) for the treatment of a rare cancer (PEComa). This chart demonstrates how productive their small commercial team and R&D department are. It reflects their ability to market this ultra-niche drug and expand its use.
Sales per employee for the market as a whole
Suburban Propane Partners (SPH) is a distributor of propane, heating oil, and other forms of energy. They deliver fuel to homes and businesses, especially in areas without access to natural gas. They operate a logistics business. This graph shows the efficiency of their distribution network. SPH's success depends on route density and the ability of their drivers and technicians to serve the maximum number of customers, which is highly dependent on weather.
Short shares by company, segment and market as a whole
Shares shorted by company Aadi Bioscience (AADI)
Aadi Bioscience (AADI) is an oncology company with one approved drug, Fyarro. This chart shows the number of short positions. Short sellers may be betting that the drug will sell slowly (due to slow physician adoption) or that it won't recoup its costs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aadi-Bioscience-AADI&v=1772513492156 "Short Shares Chart for the Company Aadi Bioscience (AADI)")
Shares shorted by market segment - Oncology targeted therapy
Aadi Bioscience (AADI) is a biopharmaceutical company focused on targeted cancer therapies (based on mTOR technology). The chart below shows the overall short position in the oncology biotech sector. It reflects investors' skepticism about the success of highly specialized clinical trials.
Shares shorted by the overall market
Aadi Bioscience (AADI) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aadi Bioscience (AADI)
This chart for Aadi Bioscience is a binary bet on their drug Fyarro. The company is targeting rare cancers associated with mTOR mutations. "Overbought" levels (above 70) arise from positive data on expanding indications. A slow sales start or failures in new trials immediately plunge the oscillator into "oversold" levels (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aadi-Bioscience-AADI&v=1772513492183 "RSI 14 indicator chart for the company's stock Aadi Bioscience (AADI)")
RSI 14 Market Segment - Oncology targeted therapy
Aadi Bioscience is a biotech company, a cancer hunter. Their specialty is targeted therapy (based on sirolimus) targeting rare tumors with the mTOR mutation. The "Oncology targeted therapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is AADI's growth driven by their R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
Aadi Bioscience (AADI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AADI (Aadi Bioscience)
Aadi Bioscience (AADI) is an oncology company whose drug Fyarro is approved for the treatment of a rare cancer type (PEComa) in patients with an mTOR mutation. This chart shows the average target price. It reflects analyst expectations for Fyarro's sales and its development for other tumors.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AADI-Aadi-Bioscience&v=1772513492233 "A chart showing analyst consensus forecasts for the expected stock price. AADI (Aadi Bioscience)")
The difference between the consensus estimate and the actual stock price AADI (Aadi Bioscience)
Aadi Bioscience (AADI) is a biopharmaceutical company focused on treating rare cancers with mutations in the TSC gene. Their drug, Fyarro, targets this specific population. This chart shows the difference between the current price and the analyst consensus estimate, reflecting their belief in the commercial potential of this ultra-niche oncology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AADI-Aadi-Bioscience&v=1772513492248 "A chart showing the difference between the consensus forecast and the actual stock price. AADI (Aadi Bioscience)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Aadi Bioscience is a biotech company focused on treating rare cancers caused by mTOR mutations (the drug Fyarro). This chart shows general expectations for the targeted oncology sector. It reflects whether experts believe in the success of "ultra-niche" oncology drugs.
Analysts' consensus forecast for the overall market share price
Aadi Bioscience (AADI) is a biopharmaceutical company focused on treating rare cancers. Their drug, Fyarro, targets tumors with the mTOR mutation. This chart shows the overall market risk appetite and serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aadi Bioscience
Aadi Bioscience is a biotech company that has crossed the finish line. They have one FDA-approved drug, Fyarro, for the treatment of an ultra-rare type of sarcoma (PEComa). This chart is a summary of their commercialization history. It reflects their (slow) sales growth rate and their R&D efforts to expand the application of their sole asset to other cancer types.
AKIMA Market Segment Index - Oncology targeted therapy
Aadi Bioscience is an oncology company specializing in targeted therapy. Their drug targets tumors with a rare mutation in the TSC gene, which is common in various cancer types. This is precision medicine. This chart compares their composite index to the sector, showing how their targeted approach compares to others.
The AKIM Index for the overall market
Aadi Bioscience is a biopharmaceutical company commercializing Fyarro, a drug for the treatment of rare cancers (PEComa). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche oncology company, focused on sales of a single product, compares to overall economic trends.
